Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904165 | 0.87 | L3MBTL1 (0.31) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| SCHEMBL8596413 | 0.83 | POLB (0.33) | NFKB1 | |
| Hydrochloric Acid SCHEMBL8380981 | 0.82 | POLB (0.33) | — | |
| SCHEMBL2804104 | 0.81 | NPC1 (0.33) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| SCHEMBL5174476 | 0.81 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL2805311 | 0.77 | NPC1 (0.30) | NPC1ALDH1A1PLA2G1BNFKB1CASP3 | |
| Chloromethane SCHEMBL7608709 | 0.77 | BRD4 (0.33) | ALDH1A1NFKB1 | |
| SCHEMBL6907164 | 0.77 | LMNA (0.31) | — | |
| SCHEMBL5083099 | 0.77 | — | — | |
| SCHEMBL1922929 | 0.77 | BRD4 (0.35) | NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785574-B2 | Bridged metallocene compound, olefin polymerization catalyst containing the same, and ethylene polymer obtained with the catalyst | MITSUI CHEMICALS, INC. (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140114031-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | PRIME POLYMER CO., LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2218725-B1 | BRIDGED METALLOCENE OLEFIN POLYMERIZATION CATALYST AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST | MITSUI CHEMICALS INC (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | MITSUI CHEMICALS, INC. | 2010-11-18 | — | — | US | disclosed |
| EP-2218725-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST USING THE COMPOUND AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST | Mitsui Chemicals, Inc. (JP) | 2010-08-18 | — | — | EP | disclosed |
| EP-2050771-A1 | FILM OR LAMINATE COMPRISING ETHYLENE RESIN OR ETHYLENE RESIN COMPOSITION | Mitsui Chemicals, Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | CAD, ENDOD1, CCT7 | NPC1 1729/4885ALDH1A1 979/4885PLA2G1B 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.